Uproleselan with pre-transplant conditioning for Acute Myeloid Leukemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Acute Myeloid Leukemia+1 MoreFludarabine - Drug
Eligibility
12 - 30
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying a new drug, uproleselan, to see if it can help leukemia patients.

Eligible Conditions
  • Acute Myeloid Leukemia
  • Pediatric Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Minnelide
1
Uproleselan
1
CD33*CD3 BsAb

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: Up to 2 years

12 months
Leukemia
Day 14
Number of Patients with Severe Oral or Gastrointestinal Mucositis
Year 2
Overall Survival (OS)
Day -8 pre- transplant through post-transplant Day +30
Recommend Phase 2 Dose
Day -8 pre-transplant to day -4 pre- transplant
Uproleselan Pharmacokinetics
Day 0
Dose Limiting Toxicity (DLT) Phase 1
Dose Limiting Toxicity (DLT) Phase 2
Up to 2 years
Relapse Rate at the RP2D

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Minnelide
1
Uproleselan
1
CD33*CD3 BsAb

Trial Design

1 Treatment Group

Uproleselan with pre-transplant conditioning
1 of 1

Experimental Treatment

28 Total Participants · 1 Treatment Group

Primary Treatment: Uproleselan with pre-transplant conditioning · No Placebo Group · Phase 1 & 2

Uproleselan with pre-transplant conditioningExperimental Group · 4 Interventions: Fludarabine, Uproleselan, Clofarabine, Busulfan · Intervention Types: Drug, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fludarabine
2012
Completed Phase 3
~1170
Uproleselan
2018
Completed Phase 2
~60
Clofarabine
2007
Completed Phase 3
~1160
Busulfan
2008
Completed Phase 3
~1110

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

John Horan, MDLead Sponsor
GlycoMimetics IncorporatedIndustry Sponsor
22 Previous Clinical Trials
1,493 Total Patients Enrolled
John HoranPrincipal InvestigatorDana-Farber Cancer Institute

Eligibility Criteria

Age 12 - 30 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a 70% or higher Lansky/Karnofsky performance status.
You have myelodysplastic syndrome.
You have a predisposition to leukemia or marrow failure syndrome other than those associated with transplant-related morbidity and mortality
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top